NEW YORK--(BUSINESS WIRE)--Viramal, ("the Company"), an emerging specialty pharmaceutical company developing therapeutics that improve the quality of women’s health, today announced that the Company's CEO, Oliver Bates, will present at the 2016 BIO International Convention in San Francisco. The presentation will take place on Tuesday, June 7, 2016 at 3:15 p.m. Pacific Time in the West Presentation Theater 4 at the Moscone Center in San Francisco, California. Mr. Bates will be joined by Viramal’s Chairman, William Bologna.
Mr. Bates will outline Viramal’s robust women’s health clinical development pipeline and strategy to produce a step change in existing female healthcare products, as well as develop innovative products that target unmet therapeutic areas, by leveraging novel platform delivery technologies that offer greater safety and efficacy. Elegant™ Vaginal Moisturizer (for the treatment of vaginal atrophy) and other products from the Elegant Vaginal platform (both OTC and prescription), plus Viramal’s only men’s health product, TestoCream (transdermal delivery in an elegant cream base without alcohol), are available for out-licensing. The Company’s platform delivery technologies are also available for out-licensing for applications beyond women’s health. The presentation will be available in the News section of the Company's website, www.viramal.com.
To schedule a meeting with Viramal’s management team at the conference, use the BIO One-on-One Partnering™ system for registered participants or contact Katja Buhrer in the Investor Relations department at email@example.com. Viramal will be taking meetings June 6-9.
Viramal is an emerging specialty pharmaceutical company focused on the development of therapeutics that improve the quality of women’s health. The Company’s well-recognized management team has pioneered market-leading products in fertility and female sexual health, having successfully developed, licensed and sold Crinone®, Replens® and RepHresh®. Viramal produces a step change in these existing products, as well as develops innovative products that target unmet therapeutic areas, by leveraging novel platform delivery technologies that offer greater safety, efficacy and patient acceptability with far fewer side effects. The Company’s robust women’s health clinical development pipeline includes treatments for fertility, menopausal hormone therapy, contraception and sexual health. In addition, Viramal’s only male product, TestoCream (transdermal delivery of testosterone), has shown 81% success in a partially completed Phase III study. Please visit www.viramal.com for more information.
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.